Sutent price (correction)
Executive Summary
Based on the wholesale acquisition cost of Sutent (sunitinib), which is $6,412.50 for a 30 count bottle of 50 mg capsules, the product's average monthly cost is $4,275. This prices Sutent at a slight discount to Bayer/Onyx' Nexavar (sorafenib) which carries a WAC of $4,333 for a one-month supply. In a previous story on the approval of Sutent, "The Pink Sheet" incorrectly identified the price of the product and incorrectly referred to the average wholesale price of Nexavar as the price to patients (1"The Pink Sheet" Jan. 30, 2006, p. 4)...
You may also be interested in...
Pfizer Oncologic Sutent Will Have Dosing, Slight Price Advantage Over Nexavar
Pfizer's newly approved oncologic Sutent will have a dosing advantage and will be priced at a slight discount compared to Bayer/Onyx' Nexavar
Robust Trial Transparency Strategy Boosts Patient Engagement
Most clinical trial sponsors view data disclosure as a mandate, maintaining regulatory compliance as a legal requirement. Study sponsors that realize the potential to repurpose this data, using a patient-first approach, turn transparency into a strategic advantage for engagement and recruitment efforts.
Medtronic’s Perfusion System Recall Is Fifth Class I In 2 Months
The Bio-Console 560 extracorporeal blood pumping console is being recalled over reports it could lose power during bypass surgery, which could lead to organ or neural dysfunction, blood clots, or even death.